The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Whole genome sequencing reveals clinically relevant alterations missed by standard testing in MDS
Alex Bataller, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses findings from a whole genome sequencing study in myelodysplastic syndromes (MDS) that identified clinically relevant genomic abnormalities missed by standard testing approaches. Dr Bataller highlights how comprehensive genomic profiling may improve prognostication in MDS by identifying novel alterations that are currently unrecognized. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
